Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial

Raja Atreya; Laurent Peyrin-Biroulet; Andrii Klymenko; Monica Augustyn; Igor Bakulin; Dusan Slankamenac; Pal Miheller; Antonio Gasbarrini; Xavier Hébuterne; Karin Arnesson; Thomas Knittel; Jan Kowalski; Markus F Neurath; William J Sandborn; Walter Reinisch

doi:10.1016/s2468-1253(20)30301-0

Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(20)30301-0 ◽

2020 ◽

Vol 5 (12) ◽

pp. 1063-1075 ◽

Cited By ~ 1

Author(s):

Raja Atreya ◽

Laurent Peyrin-Biroulet ◽

Andrii Klymenko ◽

Monica Augustyn ◽

Igor Bakulin ◽

...

Keyword(s):

Ulcerative Colitis ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Ranging

Download Full-text

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

Gut ◽

10.1136/gut.2005.089854 ◽

2006 ◽

Vol 55 (11) ◽

pp. 1568-1574 ◽

Cited By ~ 103

Author(s):

G Van Assche ◽

W J Sandborn ◽

B G Feagan ◽

B A Salzberg ◽

D Silvers ◽

...

Keyword(s):

Ulcerative Colitis ◽

Monoclonal Antibody ◽

Interleukin 2 ◽

Active Ulcerative Colitis ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 2 Receptor ◽

Dose Ranging

Download Full-text

A Phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis

Alimentary Pharmacology & Therapeutics ◽

10.1111/j.1365-2036.2006.02910.x ◽

2006 ◽

Vol 23 (10) ◽

pp. 1415-1425 ◽

Cited By ~ 86

Author(s):

S. J. H. VAN DEVENTER ◽

M. K. WEDEL ◽

B. F. BAKER ◽

S. XIA ◽

E. CHUANG ◽

...

Keyword(s):

Ulcerative Colitis ◽

Acute Exacerbation ◽

Phase Ii ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Ranging

Download Full-text

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomized, double blind, placebo controlled, dose ranging trial

Yearbook of Gastroenterology ◽

10.1016/s0739-5930(08)70104-1 ◽

2007 ◽

Vol 2007 ◽

pp. 125-126

Author(s):

G.R. Lichtenstein

Keyword(s):

Ulcerative Colitis ◽

Monoclonal Antibody ◽

Interleukin 2 ◽

Active Ulcerative Colitis ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 2 Receptor ◽

Dose Ranging

Download Full-text

Faculty Opinions recommendation of A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717967956.793467610 ◽

2012 ◽

Author(s):

Robin Steinhorn

Keyword(s):

Pulmonary Arterial Hypertension ◽

Arterial Hypertension ◽

Sildenafil Citrate ◽

Double Blind ◽

Double Blind Placebo ◽

Treatment Naïve ◽

Dose Ranging ◽

Pulmonary Arterial

Download Full-text

A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study to evaluate the efficacy and safety of VT‐1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail

British Journal of Dermatology ◽

10.1111/bjd.19224 ◽

2020 ◽

Cited By ~ 1

Author(s):

B. Elewski ◽

S. Brand ◽

T. Degenhardt ◽

S. Curelop ◽

R. Pollak ◽

...

Keyword(s):

Phase Ii ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Ranging

Download Full-text

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

The Lancet Neurology ◽

10.1016/s1474-4422(08)70173-x ◽

2008 ◽

Vol 7 (9) ◽

pp. 796-804 ◽

Cited By ~ 326

Author(s):

Benjamin M Segal ◽

Cris S Constantinescu ◽

Aparna Raychaudhuri ◽

Lilianne Kim ◽

Rosanne Fidelus-Gort ◽

...

Keyword(s):

Multiple Sclerosis ◽

Phase Ii ◽

Double Blind ◽

Subcutaneous Injections ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Dose Ranging ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

The Lancet ◽

10.1016/s0140-6736(16)30307-5 ◽

2016 ◽

Vol 388 (10039) ◽

pp. 31-44 ◽

Cited By ~ 446

Author(s):

Sally Wenzel ◽

Mario Castro ◽

Jonathan Corren ◽

Jorge Maspero ◽

Lin Wang ◽

...

Keyword(s):

Inhaled Corticosteroids ◽

Persistent Asthma ◽

High Dose ◽

Efficacy And Safety ◽

Pivotal Phase ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Ranging ◽

Long Acting ◽

Β2 Agonist

Download Full-text

Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(21)00400-3 ◽

2021 ◽

Author(s):

Craig Haifer ◽

Sudarshan Paramsothy ◽

Nadeem O Kaakoush ◽

Aiasha Saikal ◽

Simon Ghaly ◽

...

Keyword(s):

Ulcerative Colitis ◽

Controlled Trial ◽

Faecal Microbiota ◽

Double Blind ◽

Double Blind Placebo ◽

Faecal Microbiota Transplantation

Download Full-text

A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy

Journal of Psychopharmacology ◽

10.1177/0269881117722998 ◽

2017 ◽

Vol 31 (9) ◽

pp. 1190-1203 ◽

Cited By ~ 5

Author(s):

Cynthia Richards ◽

Dan V Iosifescu ◽

Rajnish Mago ◽

Elias Sarkis ◽

James Reynolds ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Antidepressant Therapy ◽

Inadequate Response ◽

Major Depressive ◽

Lisdexamfetamine Dimesylate ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Ranging

Download Full-text

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial

The Lancet ◽

10.1016/s0140-6736(11)61126-4 ◽

2011 ◽

Vol 378 (9792) ◽

pp. 676-683 ◽

Cited By ~ 216

Author(s):

John GF Cleland ◽

John R Teerlink ◽

Roxy Senior ◽

Evgeny M Nifontov ◽

John JV Mc Murray ◽

...

Keyword(s):

Heart Failure ◽

Cardiac Function ◽

Systolic Heart Failure ◽

Phase 2 ◽

Cardiac Myosin ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Omecamtiv Mecarbil ◽

Dose Ranging

Download Full-text